Literature DB >> 17877927

Perspective: effect of rosiglitazone on cardiovascular outcomes.

Steven E Nissen1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17877927     DOI： 10.1007/bf02938358

Source DB:  PubMed          Journal:  Curr Cardiol Rep        ISSN： 1523-3782            Impact factor:   2.931


× No keyword cloud information.
  4 in total

1.  Much ado about nothing: a comparison of the performance of meta-analytical methods with rare events.

Authors:  Michael J Bradburn; Jonathan J Deeks; Jesse A Berlin; A Russell Localio
Journal:  Stat Med       Date:  2007-01-15       Impact factor: 2.373

2.  Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial.

Authors:  John A Dormandy; Bernard Charbonnel; David J A Eckland; Erland Erdmann; Massimo Massi-Benedetti; Ian K Moules; Allan M Skene; Meng H Tan; Pierre J Lefèbvre; Gordon D Murray; Eberhard Standl; Robert G Wilcox; Lars Wilhelmsen; John Betteridge; Kåre Birkeland; Alain Golay; Robert J Heine; László Korányi; Markku Laakso; Marián Mokán; Antanas Norkus; Valdis Pirags; Toomas Podar; André Scheen; Werner Scherbaum; Guntram Schernthaner; Ole Schmitz; Jan Skrha; Ulf Smith; Jan Taton
Journal:  Lancet       Date:  2005-10-08       Impact factor: 79.321

3.  Effect of muraglitazar on death and major adverse cardiovascular events in patients with type 2 diabetes mellitus.

Authors:  Steven E Nissen; Kathy Wolski; Eric J Topol
Journal:  JAMA       Date:  2005-10-20       Impact factor: 56.272

4.  Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes.

Authors:  Steven E Nissen; Kathy Wolski
Journal:  N Engl J Med       Date:  2007-05-21       Impact factor: 91.245
  4 in total
  5 in total

1.  The role of insulin-sensitizing agents in the treatment of nonalcoholic steatohepatitis.

Authors:  Lisa B Van Wagner; Mary E Rinella
Journal:  Therap Adv Gastroenterol       Date:  2011-07       Impact factor: 4.409

2.  Plasma adiponectin levels and clinical outcomes among haemodialysis patients.

Authors:  Madhumathi Rao; Lijun Li; Hocine Tighiouart; Bertrand L Jaber; Brian J G Pereira; Vaidyanathapuram S Balakrishnan
Journal:  Nephrol Dial Transplant       Date:  2008-03-11       Impact factor: 5.992

3.  PPARgamma, PTEN, and the Fight against Cancer.

Authors:  Rosemary E Teresi; Kristin A Waite
Journal:  PPAR Res       Date:  2008-12-14       Impact factor: 4.964

4.  Neuroprotective Properties of a Novel Non-Thiazoledinedione Partial PPAR- γ Agonist against MPTP.

Authors:  Christine R Swanson; Eric Du; Delinda A Johnson; Jeffrey A Johnson; Marina E Emborg
Journal:  PPAR Res       Date:  2013-10-02       Impact factor: 4.964

5.  Characterization of an Agarophyton chilense Oleoresin Containing PPARγ Natural Ligands with Insulin-Sensitizing Effects in a C57Bl/6J Mouse Model of Diet-Induced Obesity and Antioxidant Activity in Caenorhabditis elegans.

Authors:  Claudio Pinto; María Raquel Ibáñez; Gloria Loyola; Luisa León; Yasmin Salvatore; Carla González; Víctor Barraza; Francisco Castañeda; Rebeca Aldunate; Loretto Contreras-Porcia; Karen Fuenzalida; Francisca C Bronfman
Journal:  Nutrients       Date:  2021-05-27       Impact factor: 5.717
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.